EN | RU
EN | RU

Help Support

Back

A leading pharmaceutical collaborates with IAVI on COVID-19 Vaccine

A leading pharmaceutical collaborates with IAVI on COVID-19 Vaccine A leading pharmaceutical collaborates with IAVI on COVID-19 Vaccine
A leading pharmaceutical collaborates with IAVI on COVID-19 Vaccine A leading pharmaceutical collaborates with IAVI on COVID-19 Vaccine

What's new?

Using the recombinant vesicular stomatitis virus (rVSV) technology can have the potential for future vaccination for COVID-19.

In the quest to find a vaccine against COVID-19 or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a leading American pharmaceutical is working together with IAVI (a nonprofit scientific research organization).

The vaccine will be produced through recombinant vesicular stomatitis virus (rVSV) technology, in a similar manner by which earlier the vaccine for Ebola virus was developed. The researchers have swapped the vesicular stomatitis virus (VSV) gene coding for the VSV surface protein with a gene coding for SARS-CoV-2 surface protein to generate an immune response. Presently, this vaccine candidate is in preclinical development phase. The clinical studies are anticipated to start at year end.

This is also working on developing an oral antiviral candidate for COVID-19 treatment. This candidate is a ribonucleoside analog that prevents the RNA virus replication comprising SARS-CoV-2. 

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: